Comparative Pharmacology
Head-to-head clinical analysis: FEMLYV versus HAILEY FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEMLYV versus HAILEY FE 1 5 30.
FEMLYV vs HAILEY FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Category C
Category C
Oral Contraceptive
Oral Contraceptive